Fredrik Dahl
Born 1977
Interim CEO since 2025
PhD in molecular medicine, Uppsala University, postdoctoral studies at Stanford Genome Technology Center, Stanford University.
Other important offices:
Chair of the Board of Pixelgen Technologies AB, board member of Mindforce Game Lab AB, Nucleus Capital AB and Colibri Ventures AB.
Previous positions:
Co-Founder and CTO of Vanadis Diagnostics AB and Halo Genomics AB.
Shares: 34,150 Company shares.
Sabina Berlin
Born in 1983
CFO since 2021
Education:
M.Sc. in Business and Economics, Gothenburg School of Business.
Other important offices:
Director of Zymology AB.
Previous positions:
CEO of Juno Ekonomi AB, CFO of IRRAS AB.
Holdings in the company:
Number of shares: 4,675
Employee stock options (Program 2023/2027): 20,000
Employee stock options (Program 2024/2028): 25,000
Theis Kipling
Born in 1982
CCO since 2022
Education:
Master's degree in Business Administration, Copenhagen Business School.
Other important offices: -
Previous positions:
CCO of Atlas Antibodies, international management positions in marketing/sales at Agilent, Global Brand Management at Lundbeck A/S.
Holdings in the company:
Number of shares: 16,504
Employee stock options (Program 2022/2025): 60,000
Employee stock options (Program 2023/2027): 20,000
Employee stock options (Program 2024/2028): 7,500
Camilla Wiberg
Born 1979
CHRO since 2022
Education:
Master's degree in Human Resources Management, Linköping University.
Other important offices: -
Previous positions:
Interim HR Consultant and HR Manager at Orkla Care AB and Avanade Sweden AB.
Holdings in the company:
Number of shares: 200
Employee stock options (Program 2022/2025): 40,000
Employee stock options (Program 2023/2027): 10,000
Michael Uhlin
Born 1978
CSO since 2023
Education:
Masters in Biomedicine, Karolinska Institutet, Stockholm. PhD in Infection biology, Karolinska Institutet. Postdoctoral studies at Karolinska University hospital in Transplantation Immunology.
Other important offices:
Adjunct Professor in Clinical Immunology at Karolinska Institutet.
Previous positions:
CSO in XNK Therapeutics. Head of Clinical Immunology at Karolinska University Hospital. Head of Development and IT at Karolinska University Hospital. Head of division Therapeutic Immunology and Transfusion Medicine at Karolinska Institutet. Head of Research at Karolinska University Hospital.
Holdings in the company:
Number of shares: -
Employee stock options (Program 2023/2027): 40,000
Employee stock options (Program 2024/2028): 5,000